Professor Claude M. Wischik, co-founder and Executive Chairman of TauRx Therapeutics, along with colleagues at the University of Aberdeen, has devoted nearly 30 years to investigating the structure and role of tau tangles in the development of Alzheimer’s, frontotemporal dementia and other neurodegenerative diseases. Prof. Wischik discovered that the neurofibrillary tangles seen in Alzheimer’s disease are made of sub-units of the tau protein and he and his team have published extensively in the field.
Filter by yearAll 2022 2021 2020 2019 2018 2017 2016 2015 2014 2012 2011 2010 2009 2008 2007 2006 2005 2001 2000 1998 1997 1996 1995 1994 1993 1992 1991 1990 1988 1986 1985
Lutter, L., et al (2022) Structural Identification of Individual Helical Amyloid Filaments by Integration
of Cryo-Electron Microscopy-Derived Maps in Comparative Morphometric Atomic Force Microscopy Image Analysis. Available at Journal of Molecular Biology
Santos. R.X., et al (2022) HMTM-Mediated Enhancement of Brain Bioenergetics in a
Mouse Tauopathy Model Is Blocked by Chronic Administration
of Rivastigmine. Available at Biomedicines
Wischik, C.M., et al (2022) Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. Available at The Journal of Prevention of Alzheimer's Disease